anti-CSPG4 CAR T-cell therapy (Bellicum Pharmaceuticals/UNC Lineberger Comprehensive Cancer Center)

N/A

Report date: 2025/06/11 10:27:49

Base Information

Drug Nameanti-CSPG4 CAR T-cell therapy (Bellicum Pharmaceuticals/UNC Lineberger Comprehensive Cancer Center)
Drug Alias NameiC9-CAR.CSPG4 T cell therapy (Bellicum Pharmaceuticals/UNC Lineberger Comprehensive Cancer Center)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionApoptosis stimulantsT lymphocytes stimulantsChondroitin sulfate proteoglycan 4 modulators +[4] 
TargetsChondroitin sulfate proteoglycan 4
Therapy Area/IndicationsPharyngeal NeoplasmsLaryngeal NeoplasmsMouth Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUnc Lineberger Comprehensive Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesBellicum Pharmaceuticals IncUnc Lineberger Comprehensive Cancer Center
Inactive CompaniesN/A
Active IndicationsPharyngeal NeoplasmsLaryngeal NeoplasmsMouth Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A